Webseite
http://www.clinicaloptions.com/Oncology ... s/MDS.aspx
Studien:
* Higher Relapse Rate When Ara-C Omitted From Daunorubicin-Based Regimens in Newly Diagnosed Patients With Standard-Risk APL
* Mutations in DNA Methyltransferase Gene DNMT3A Prevalent in Intermediate-Risk AML and Portend Poor Prognosis
* Dasatinib Combined With Low-Dose Chemotherapy Produces High and Durable Rates of Remission in Older Patients Newly Diagnosed With Ph-Positive ALL
* Lenalidomide Monotherapy Benefits < 15% of Older Patients With Acute Myeloid Leukemia and del(5q)
* Adding Sorafenib to Standard 7+3 Induction Therapy Does Not Benefit Older Patients With AML
* Outcomes Poor for Patients With Higher-Risk MDS or Secondary AML Who Receive Salvage Therapy After Azacitidine Failure
* No Improvement in Trilineage Response With Entinostat Plus Azacitidine vs Azacitidine Alone in MDS and AML Patients With Myelodysplasia-Related Changes
* Trend Toward Improved Survival With Liposomal vs Standard Formulation of Cytarabine/Daunorubicin in Treatment-Naive, Elderly Patients with AML
* GATA2 Germline Mutations T354M and 355delT Segregate Among Family Members With MDS/AML: T354M Activates Cell Survival Transcripts
- Kostenlose - Regstrierung ist erforderlich, wenn man mehr Infos möchte. Expertenmeinungen -leider alle auf Englisch - werden folgen.
LG Akita / Margarete
